PMCTPharmaCountry
    Accueil
Recherches & Rapports30 août 2026•1 min de lecture

AI in Pharma Faces Data‑Gathering Delays, Not Scientific Limits

Par l'équipe PharmaCountry

A recent note says most of the two‑week deviation investigation time is spent on data collection, not science, highlighting a bottleneck for AI tools in pharma.

Most of those two weeks is not science. It is finding and assembling the data, which is also where most of the AI sold to pharma quietly stalls.

Compilé par l'équipe PharmaCountry · Source : FiercePharma

Sujets :#AI#pharma#data management#deviation investigation#regulatory compliance

Plus d'articles

Voir tous les articles
Recherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementaires
Korea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
Analyse
Pharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026